IPA Stock Overview
A techbio company, engages in the development of therapeutic antibodies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.43 |
| 52 Week High | US$1.39 |
| 52 Week Low | US$0.27 |
| Beta | 0.38 |
| 1 Month Change | 12.06% |
| 3 Month Change | -6.24% |
| 1 Year Change | -65.22% |
| 3 Year Change | -92.19% |
| 5 Year Change | -85.13% |
| Change since IPO | -90.06% |
Recent News & Updates
Recent updates
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely
Jan 17
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 24ImmunoPrecise Antibodies reports FQ1 results
Sep 14ImmunoPrecise’s polytope program reduces lung inflammation in SARS-CoV-2 challenged hamsters
Jun 17Shareholder Returns
| IPA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.7% | 1.2% | 5.8% |
| 1Y | -65.2% | -26.6% | 4.8% |
Return vs Industry: IPA underperformed the US Life Sciences industry which returned -26.6% over the past year.
Return vs Market: IPA underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| IPA volatility | |
|---|---|
| IPA Average Weekly Movement | 16.5% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: IPA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IPA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 87 | Jennifer Bath | www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., a techbio company, engages in the development of therapeutic antibodies. It leverages multi-omics modeling and artificial intelligence through a series of proprietary and patented technologies. The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| IPA fundamental statistics | |
|---|---|
| Market cap | US$19.74m |
| Earnings (TTM) | -US$33.71m |
| Revenue (TTM) | US$17.31m |
1.1x
P/S Ratio-0.6x
P/E RatioIs IPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPA income statement (TTM) | |
|---|---|
| Revenue | CA$24.00m |
| Cost of Revenue | CA$11.80m |
| Gross Profit | CA$12.20m |
| Other Expenses | CA$58.94m |
| Earnings | -CA$46.74m |
Last Reported Earnings
Jan 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 50.82% |
| Net Profit Margin | -194.79% |
| Debt/Equity Ratio | 0% |
How did IPA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 08:36 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2025/01/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunoPrecise Antibodies Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Tania Armstrong-Whitworth | Cormark Securities Inc. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |